Clinical profile of patients with secondary immunodeficiency on immunoglobulin replacement therapy
Main Article Content
Keywords
Immunologic Deficiency Syndromes, Immunoglobulins, Intravenous, Glucocorticoids, Rituximab, Autoimmune Diseases
Abstract
Abstract
Background: Secondary immunodeficiency (SID) is a disorder in which the immune system is compromised by external or acquired factors, reducing the quantity or function of immunoglobulins. This condition increases the need for specialist consultation, follow-up, and replacement therapy, which in turn raises healthcare costs. To date, few studies have clinically characterized patients with SID; therefore, understanding their profile will enable improved management and treatment.
Objective: To describe the clinical profile of patients with SID receiving human immunoglobulin replacement therapy (IgG-RT).
Material and methods: A retrospective observational study was conducted through the review of 40 medical records of patients with SID undergoing IgG-RT. Risk factors and the benefits of replacement therapy were analyzed.
Results: The mean age was 48 years, with a predominance of women (62.5%). The most frequent conditions were rheumatologic diseases (38%), followed by hematologic disorders (31%) and protein-losing diseases (27%). All patients had received corticosteroids in combination with another immunosuppressant, and 77.5% had also been treated with rituximab. Infections were recorded in 50% of cases; however, only 35% received prophylaxis. Relapse was documented in 22.5% of patients, and mortality was 2.5%.
Conclusions: The use of corticosteroids and immunosuppressants, specifically rituximab, was the main cause of SID, predominantly associated with rheumatologic and hematologic diseases.
References
1. Hernández-Martínez C, Espinosa-Rosales FJ, Espinosa-Padilla SE, et al. Conceptos básicos de las inmunodeficiencias primarias. Rev Alerg México. el 11 de mayo de 2016;63(2):180–9. DOI:10.29262/ram.v63i2.146
2. Hillion S, Arleevskaya MI, Blanco P, Bordron A, et al. The Innate Part of the Adaptive Immune System. Clin Rev Allergy Immunol. abril de 2020;58(2):151–4. DOI: 10.1007/s12016-019-08740-1
3. Tuano KS, Seth N, Chinen J. Secondary immunodeficiencies: An overview. Ann Allergy Asthma Immunol. el 1 de diciembre de 2021;127(6):617–26. DOI: 10.1016/j.anai.2021.08.413
4. Otani IM, Lehman HK, Jongco AM, Tsao LR, Azar AE, Tarrant TK, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. J Allergy Clin Immunol. el 1 de mayo de 2022;149(5):1525–60.DOI: 10.1016/j.jaci.2022.01.025
5. Inmunodeficiencias secundarias relacionadas con la presencia de autoanticuerpos anticitocinas [Internet]. [citado el 27 de marzo de 2025]. Disponible en: https://www.scielo.org.mx/scielo.php?pid=S001638132023000200157&script=sci_arttext
6. Kapadia RK, Staples JE, Gill CM, Fischer M, Khan E, Laven JJ, et al. Severe Arboviral Neuroinvasive Disease in Patients on Rituximab Therapy: A Review. Clin Infect Dis. el 15 de marzo de 2023;76(6):1142–8. DOI: 10.1093/cid/ciac766
7. Clarke WA, Chatelut E, Fotoohi AK, Larson RA, Martin JH, Mathijssen RHJ, et al. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. Eur J Cancer. el 1 de noviembre de 2021;157:428–40. DOI: 10.1016/j.ejca.2021.08.033
8. Aldeguer Esquerdo A. Tratamientos combinados mediante carbón activado y ozono para reducir la presencia de atrazina, simazina, carbamazepina y diclofenaco en medio acuoso [Internet] [http://purl.org/dc/dcmitype/Text]. Universitat d’Alacant / Universidad de Alicante; 2022 [citado el 27 de marzo de 2025]. p. 1. Disponible en: https://dialnet.unirioja.es/servlet/tesis?codigo=313976
9. Durand CM, Massie A, Florman S, Liang T, Rana MM, Friedman-Moraco R, et al. Safety of Kidney Transplantation from Donors with HIV. N Engl J Med. el 17 de octubre de 2024;391(15):1390–401. DOI: 10.1056/NEJMoa2403733
10. Ballow M, Sánchez-Ramón S, Walter JE. Secondary Immune Deficiency and Primary Immune Deficiency Crossovers: Hematological Malignancies and Autoimmune Diseases. Front Immunol [Internet]. el 18 de julio de 2022 [citado el 8 de diciembre de 2024];13. Disponible en: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.928062/full
11. Mogica Martínez, MD. Abordaje Clínico y Terapéutico Actualizado en Inmunodeficiencias y enfermedades Autoinmunes e Inflamatorias. (2024), Editorial ZarPra. Disponible en: https://isbnmexico.indautor.cerlalc.org/catalogo.php?mode=detalle&nt=435463
12. Szepanowski F, Warnke C, Meyer zu Hörste G, Mausberg AK, Hartung HP, Kleinschnitz C, et al. Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology. CNS Drugs. el 1 de noviembre de 2021;35(11):1173–88. DOI: 10.1007/s40263-021-00863-4
13. Jahnz-Różyk K, Więsik-Szewczyk E, Roliński J, Siedlar M, Jędrzejczak W, Sydor W, et al. Secondary immunodeficiencies with predominant antibody deficiency: multidisciplinary perspectives of Polish experts. Cent Eur J Immunol. 2020;45(3):334–41. DOI: 10.5114/ceji.2020.101265
14. Pimenta FMCA, Palma SMU, Constantino-Silva RN, Grumach AS. Hypogammaglobulinemia: a diagnosis that must not be overlooked. Braz J Med Biol Res. el 10 de octubre de 2019;52:e8926. DOI: 10.1590/1414-431X20198926
15. Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol. el 1 de junio de 2017;188(3):333–41. DOI: 10.1111/cei.12915
16. Dvorak CC, Haddad E, Heimall J, Dunn E, Buckley RH, Kohn DB, et al. The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions. J Allergy Clin Immunol. febrero de 2023;151(2):539–46. DOI: 10.1016/j.jaci.2022.10.022
17. Wilson BE, Freeman CM. Immunoglobulin therapy for immunodeficiency. Allergy Asthma Proc. el 1 de septiembre de 2024;45(5):364–70. DOI: 10.2500/aap.2024.45.240053
18. Richter A. Current experience with manual push subcutaneous immunoglobulin (SCIg) in patients with immune deficiencies. Immunol Med. 2025 Jun 24:1-12. doi: 10.1080/25785826.2025.2515333.
19. Athni TS, Barmettler S. Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. junio de 2023;130(6):699–712. DOI: 10.1016/j.anai.2023.01.018
20. Unidad de Humanidades y Ética Médica [Internet]. [citado el 28 de marzo de 2025]. “Código” de Nuremberg sobre ética de la investigación en seres humanos. Material de Bioética. Unidad de Humanidades y Ética Médica. Disponible en: https://www.unav.edu/web/unidad-de-humanidades-y-etica-medica/material-de-bioetica/el-codigo-de-nuremberg
21. WMA - The World Medical Association-Declaración de Helsinki de la AMM – Principios éticos para las investigaciones médicas en seres humanos [Internet]. [citado el 5 de febrero de 2024]. Disponible en: https://www.wma.net/es/policies-post/declaracion-de-helsinki-de-la-amm-principios-eticos-para-las-investigaciones-medicas-en-seres-humanos/
22. Ley General de Salud. de Diputados, C., Congreso de, D. H., & Unión, L. A. (2024). Reglamento de la ley general de salud en materia de investigación para la salud. https://www.diputados.gob.mx/
23. Ley Federal de Protección de Datos Personales en Posesión de los Particulares. de Diputados, C., Congreso de, D. H., & Unión, L. A. (2025). Ley Federal de Protección de Datos Personales en Posesión de los Particulares. https://www.diputados.gob.mx/LeyesBiblio/pdf/LFPDPPP.pdf
24. Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. el 10 de mayo de 2023;1–16. DOI: 10.1038/s41581-023-00720-1
25. Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care Res. agosto de 2024;76(8):1051–69. DOI: 10.1002/acr.25348
26. Lanzillotta M, Della-Torre E, Milani R, Bozzolo E, Bozzalla-Cassione E, Rovati L, et al. Effects of glucocorticoids on B-cell subpopulations in patients with IgG4-related disease. Clin Exp Rheumatol. 2019;37 Suppl 118(3):159–66. PMID: 30652677
27. Carden MA, Gaddh M, Hoskote A, Brown M, Merrill V, Stowell SR, et al. Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx. Blood Adv. el 6 de febrero de 2020;4(3):477–81. DOI: 10.1182/bloodadvances.2019001148
28. Mustafa SS. Steroid-induced secondary immune deficiency. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. junio de 2023;130(6):713–7. DOI: 10.1016/j.anai.2023.01.010
29. Gray PE, David C. Inborn Errors of Immunity and Autoimmune Disease. J Allergy Clin Immunol Pract. junio de 2023;11(6):1602–22. DOI: 10.1016/j.jaip.2023.04.018
30. Cannon L, Pan A, Kovalick L, Sarkissian A, Wu EY. Secondary immunodeficiencies and infectious considerations of biologic immunomodulatory therapies. Ann Allergy Asthma Immunol. el 1 de junio de 2023;130(6):718–26. DOI: 10.1016/j.anai.2023.02.010
31. Losonczy H, Nagy Á, Kosztolányi S, Tóth O, Csalódi R, Hussain A, et al. [Correlations between secondary hypogammaglobulinaemia, infections and mortality and the need for preventive immunoglobulin replacement in patients with chronic lymphoid leukaemia]. Orv Hetil. el 1 de septiembre de 2019;160(38):1487–94. DOI: 10.1556/650.2019.31335
32. Tiddens HAWM, Meerburg JJ, Eerden MM van der, Ciet P. The radiological diagnosis of bronchiectasis: what’s in a name? Eur Respir Rev [Internet]. el 17 de junio de 2020 [citado el 30 de marzo de 2025];29(156). Disponible en: https://publications.ersnet.org/content/errev/29/156/190120
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.